Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement

ABSTRACTBackground and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anti...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Bérengère Macabeo, Liam Wilson, Jianwei Xuan, Ruichen Guo, Petar Atanasov, Linda Zheng, Clement François, Philippe Laramée
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-12-01
Saila:	Journal of Market Access & Health Policy
Gaiak:	National Reimbursement Drug List innovative drug access pricing reimbursement decision making health technology assessment
Sarrera elektronikoa:	https://www.tandfonline.com/doi/10.1080/20016689.2023.2218633
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!